Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Buys 9,708 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 9,708 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average cost of $3.29 per share, for a total transaction of $31,939.32. Following the acquisition, the director owned 219,018 shares of the company’s stock, valued at $720,569.22. This represents a 4.64% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Sachetta also recently made the following trade(s):

• On Thursday, August 27th, Eric Sachetta acquired 10,925 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.18 per share, with a total value of $34,741.50.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Up 3.9%

NASDAQ:SRTS traded up $0.13 during midday trading on Friday, hitting $3.50. 62,187 shares of the company were exchanged, compared to its average volume of 64,747. The company has a fifty day simple moving average of $3.04 and a 200 day simple moving average of $3.52. Sensus Healthcare, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $5.49. The company has a market capitalization of $57.61 million, a PE ratio of -3.72 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Lake Street Capital lowered their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Institutional Investors Weigh In On Sensus Healthcare

Several large investors have recently modified their holdings of SRTS. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare during the second quarter worth $49,000. BlackRock Inc. acquired a new position in Sensus Healthcare in the 2nd quarter valued at $252,000. Bank of New York Mellon Corp purchased a new position in Sensus Healthcare during the 2nd quarter worth $303,000. North Star Investment Management Corp. acquired a new stake in shares of Sensus Healthcare in the 1st quarter worth $500,000. Finally, XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the 4th quarter worth $77,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.